An investment analyst recommends biotech investors put their money into adult stem cells.
Based in California, SmallCap Sentinel has been issuing investment information for 23 years and analyst D.R. Clark says adult stem cell research firms are a better buy.
"As the headline-grabbing battle regarding embryonic stem cell research rages, adult stem cell sources continue to provide an ever-broadening array of life-improving possibilities," Clark said in a statement LifeNews.com obtained.
"Researchers are using the far less controversial adult stem cells to attack enormous medical problems and are confident enough in their successes thus far to seek the protection of U.S. Patents," he added.
UPDATE 8/10: More investment analysts are bullish on adult stem cells.
"From a Wall Street perspective, adult stem cells are a much better investment," Stephen Dunn of Dawson James Securities, told CNN. "These are the guys who are going to be in the news in 2007 and 2008."
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," Dunn added. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
No comments:
Post a Comment